TY  - JOUR
AU  - Wagemann, Olivia
AU  - Liu, Haiyan
AU  - Wang, Guoqiao
AU  - Shi, Xinyu
AU  - Bittner, Tobias
AU  - Scelsi, Marzia A.
AU  - Farlow, Martin R.
AU  - Clifford, David B.
AU  - Supnet-Bell, Charlene
AU  - Santacruz, Anna M.
AU  - Aschenbrenner, Andrew J.
AU  - Hassenstab, Jason J.
AU  - Benzinger, Tammie L. S.
AU  - Gordon, Brian A.
AU  - Coalier, Kelley A.
AU  - Cruchaga, Carlos
AU  - Ibanez, Laura
AU  - Perrin, Richard J.
AU  - Xiong, Chengjie
AU  - Li, Yan
AU  - Morris, John C.
AU  - Lah, James J.
AU  - Berman, Sarah B.
AU  - Roberson, Erik D.
AU  - van Dyck, Christopher H.
AU  - Galasko, Douglas
AU  - Gauthier, Serge
AU  - Hsiung, Ging-Yuek R.
AU  - Brooks, William S.
AU  - Pariente, Jérémie
AU  - Mummery, Catherine J.
AU  - Day, Gregory S.
AU  - Ringman, John M.
AU  - Mendez, Patricio Chrem
AU  - St. George-Hyslop, Peter
AU  - Fox, Nick C.
AU  - Suzuki, Kazushi
AU  - Okhravi, Hamid R.
AU  - Chhatwal, Jasmeer
AU  - Levin, Johannes
AU  - Jucker, Mathias
AU  - Sims, John R.
AU  - Holdridge, Karen C.
AU  - Proctor, Nicholas K.
AU  - Yaari, Roy
AU  - Andersen, Scott W.
AU  - Mancini, Michele
AU  - Llibre-Guerra, Jorge
AU  - Bateman, Randall J.
AU  - McDade, Eric
AU  - Daniels, Alisha J.
AU  - Courtney, Laura
AU  - Xu, Xiong
AU  - Lu, Ruijin
AU  - Gremminger, Emily
AU  - Franklin, Erin
AU  - Ibanez, Laura
AU  - Jerome, Gina
AU  - Herries, Elizabeth
AU  - Stauber, Jennifer
AU  - Baker, Bryce
AU  - Minton, Matthew
AU  - Goate, Alison M.
AU  - Renton, Alan E.
AU  - Picarello, Danielle M.
AU  - Hornbeck, Russ
AU  - Chen, Allison
AU  - Chen, Charles
AU  - Flores, Shaney
AU  - Joseph-Mathurin, Nelly
AU  - Jarman, Steve
AU  - Jackson, Kelley
AU  - Keefe, Sarah
AU  - Koudelis, Deborah
AU  - Massoumzadeh, Parinaz
AU  - McCullough, Austin
AU  - McKay, Nicole
AU  - Nicklaus, Joyce
AU  - Pulizos, Christine
AU  - Wang, Qing
AU  - Sabaredzovic, Edita
AU  - Smith, Hunter
AU  - Scott, Jalen
AU  - Simmons, Ashlee
AU  - Rizzo, Jacqueline
AU  - Smith, Jennifer
AU  - Stout, Sarah
AU  - Karch, Celeste M.
AU  - Marsh, Jacob
AU  - Holtzman, David M.
AU  - Barthelemy, Nicolas
AU  - Xu, Jinbin
AU  - Noble, James M.
AU  - Ikonomovic, Snezana
AU  - Nadkarni, Neelesh K.
AU  - Graff-Radford, Neill R.
AU  - Ikeuchi, Takeshi
AU  - Kasuga, Kensaku
AU  - Niimi, Yoshiki
AU  - Huey, Edward D.
AU  - Salloway, Stephen
AU  - Schofield, Peter R.
AU  - Bechara, Jacob A.
AU  - Martins, Ralph
AU  - Cash, David M.
AU  - Ryan, Natalie S.
AU  - Laske, Christoph
AU  - Hofmann, Anna
AU  - Kuder-Buletta, Elke
AU  - Gräber-Sultan, Susanne
AU  - Obermueller, Ulrike
AU  - Rödenbeck, Yvonne Esther
AU  - Vӧglein, Jonathan
AU  - Lee, Jae-Hong
AU  - Roh, Jee Hoon
AU  - Sanchez-Valle, Raquel
AU  - Rosa-Neto, Pedro
AU  - Allegri, Ricardo F.
AU  - Surace, Ezequiel
AU  - Vazquez, Silvia
AU  - Lopera, Francisco
AU  - Leon, Yudy Milena
AU  - Ramirez, Laura
AU  - Aguillon, David
AU  - Levey, Allan I.
AU  - Johnson, Erik C. B
AU  - Seyfried, Nicholas T.
AU  - Fagan, Anne M.
AU  - Mori, Hiroshi
AU  - Masters, Colin
TI  - Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease
JO  - JAMA neurology
VL  - 81
IS  - 6
SN  - 2168-6149
CY  - Chicago, Ill.
PB  - American Medical Association
M1  - DZNE-2024-00567
SP  - 582 - 593
PY  - 2024
AB  - Importance  Effects of antiamyloid agents, targeting either fibrillar or soluble monomeric amyloid peptides, on downstream biomarkers in cerebrospinal fluid (CSF) and plasma are largely unknown in dominantly inherited Alzheimer disease (DIAD).Objective  To investigate longitudinal biomarker changes of synaptic dysfunction, neuroinflammation, and neurodegeneration in individuals with DIAD who are receiving antiamyloid treatment.Design, Setting, and Participants  From 2012 to 2019, the Dominantly Inherited Alzheimer Network Trial Unit (DIAN-TU-001) study, a double-blind, placebo-controlled, randomized clinical trial, investigated gantenerumab and solanezumab in DIAD. Carriers of gene variants were assigned 3:1 to either drug or placebo. The present analysis was conducted from April to June 2023. DIAN-TU-001 spans 25 study sites in 7 countries. Biofluids and neuroimaging from carriers of DIAD gene variants in the gantenerumab, solanezumab, and placebo groups were analyzed.Interventions  In 2016, initial dosing of gantenerumab, 225 mg (subcutaneously every 4 weeks) was increased every 8 weeks up to 1200 mg. In 2017, initial dosing of solanezumab, 400 mg (intravenously every 4 weeks) was increased up to 1600 mg every 4 weeks.Main Outcomes and Measures  Longitudinal changes in CSF levels of neurogranin, soluble triggering receptor expressed on myeloid cells 2 (sTREM2), chitinase 3–like 1 protein (YKL-40), glial fibrillary acidic protein (GFAP), neurofilament light protein (NfL), and plasma levels of GFAP and NfL.Results  Of 236 eligible participants screened, 43 were excluded. A total of 142 participants (mean [SD] age, 44 [10] years; 72 female [51
LB  - PUB:(DE-HGF)16
C6  - pmid:38683602
DO  - DOI:10.1001/jamaneurol.2024.0991
UR  - https://pub.dzne.de/record/269526
ER  -